Nortech Systems Incorporated NSYS PHARMA
Company Overview
Nortech Systems Incorporated provides engineering design and manufacturing solutions for electromedical devices, electromechanical systems, assemblies, and components in the United States, Mexico, and China. It offers a range of value-added engineering, technical, manufacturing, and support services, including project management, designing, testing, prototyping, manufacturing, supply chain management, and post-market services. The company also manufacturing and engineering services that include complex electromedical and electromechanical product, such as medical devices, wire and cable assemblies, printed circuit board assemblies, complex higher-level assemblies, and other box builds for a range of industries. In addition, it offers engineering and repair services. The company serves original equipment manufacturers in the medical devices and imaging, aerospace and defense, and industrial markets through business development teams and independent manufacturers' representatives. Nortech Systems Incorporated was founded in 1990 and is headquartered in Maple Grove, Minnesota.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $118.36M (-7.6% YoY); net profit $-252.00K.
- Trailing 12 Months Year-on-year growth — revenue +9.3%, earnings -2.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.22% |
| 1 Year: | 9.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -2.50% |
Stock Price Performance
| 1 Year: | +34.35% |
| 6 Months: | +26.79% |
| 3 Months: | -28.13% |
| 1 Month: | -24.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.38 · Neutral
P/E of 32.56 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 33.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NSYS Nortech Systems Incorporated PHARMA | 11.72 | 32.56 | $33.45M | 0.00% | 2.95% | 3.00% | 1.22% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 28.31M | 26.45M | 28.54M | 29.56M | 28.16M | 27.29M | 30.06M | 27.44M | 26.46M | 26.36M | 22.07M | 30.18M | 29.45M | 30.71M | 32.52M | 35.28M | 34.89M | 35.02M | 33.37M | 34.22M | 33.89M | 31.41M | - | 26.89M | 30.68M | 30.48M | 30.31M | 30.32M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.82M | 25.84M | 25.46M | 25.25M | 25.61M |
| Gross Profit | 3.02M | 3.07M | 3.28M | 3.53M | 2.87M | 2.43M | 2.89M | 3.38M | 3.12M | 3.79M | 3.09M | 3.37M | 3.52M | 3.03M | 3.82M | 3.39M | 2.96M | 2.33M | 3.63M | 3.00M | 2.73M | 1.96M | 1.56M | 3.58M | 8.04M | 4.04M | 5.00M | 6.33M | 5.48M | 5.47M | 5.32M | 5.45M | 4.62M | 3.83M | - | 3.08M | 4.84M | 5.03M | 5.07M | 4.70M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.42M | 4.09M | 4.08M | 4.17M | 4.66M |
| Operating Income | 376.18K | 236.22K | 347.18K | 473.49K | -201.60K | -483.36K | -65.65K | 220.95K | -109.94K | 189.76K | 121.00K | 95.00K | 284.00K | -120.00K | 734.00K | 649.00K | -104.00K | -1.21M | 713.00K | 391.00K | 49.00K | 2.71M | -2.17M | 406.00K | 4.92M | 169.00K | 1.02M | 1.95M | 1.05M | 1.10M | 1.12M | 1.16M | 344.00K | -467.00K | - | -1.35M | 742.00K | 945.00K | 901.00K | 47.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.27M | 1.07M | 1.25M | 1.20M | 350.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 214.00K | 257.00K | 273.00K | 220.00K | 256.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.83M | 485.00K | 672.00K | 681.00K | -209.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -511.00K | 172.00K | 818.00K | -216.00K | -175.00K |
| Net Income | 217.92K | 86.16K | 246.70K | 332.70K | -192.79K | -378.36K | -123.61K | 62.93K | -180.18K | 63.31K | -15.00K | -16.00K | 43.00K | -391.00K | 390.00K | 364.00K | -363.00K | -1.55M | 413.00K | 137.00K | -123.00K | 1.97M | -1.55M | 179.00K | 3.56M | 138.00K | 719.00K | 1.53M | 681.00K | 634.00K | 1.21M | 765.00K | 157.00K | -739.00K | - | -1.32M | 313.00K | -146.00K | 897.00K | -34.00K |
| Diluted EPS | 0.07 | 0.03 | 0.09 | 0.12 | -0.07 | -0.14 | -0.05 | 0.02 | -0.07 | 0.02 | -0.01 | -0.01 | 0.02 | - | - | 0.14 | -0.14 | -0.58 | 0.16 | 0.06 | -0.05 | 0.73 | -0.58 | 0.06 | 1.24 | 0.05 | 0.25 | 0.53 | 0.23 | 0.22 | 0.42 | 0.26 | 0.05 | -0.27 | - | -0.48 | 0.12 | -0.05 | 0.31 | -0.01 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 207.00K | 141.00K | 328.00K | 351.00K | 475.00K | 276.00K | 317.00K | 314.00K | 318.00K | 291.00K | 284.00K | - | 326.00K | 302.00K | 266.00K | - | 310.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99.82M | 114.24M | 106.94M | 111.06M | 112.04M | 115.19M | 116.62M | 112.33M | 113.37M | 116.33M | 104.11M | - | 134.12M | 139.33M | 128.13M | 118.36M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 113.64M | 116.23M | 111.41M | 100.36M |
| Gross Profit | 11.43M | 13.34M | 12.39M | 13.12M | 13.33M | 12.06M | 13.84M | 12.12M | 13.31M | 12.58M | 9.66M | - | 20.48M | 23.10M | 16.72M | 18.01M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 16.61M | 17.15M | 16.35M | 16.77M |
| Operating Income | 1.23M | 1.51M | 1.46M | 1.46M | 1.33M | -422.05K | 629.06K | -1.27M | 1.25M | 224.00K | -616.00K | - | 3.87M | 5.95M | 376.00K | 1.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 5.81M | 8.00M | 1.54M | 2.26M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 411.00K | 487.00K | 744.00K | 964.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | 3.48M | 5.47M | -939.00K | 11.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 1.47M | -1.41M | 356.00K | 263.00K |
| Net Income | 506.77K | 1.19M | 629.44K | 787.38K | 880.02K | -571.42K | 43.77K | -2.45M | 166.00K | -1.23M | -1.55M | - | 2.01M | 6.87M | -1.29M | -252.00K |
| Diluted EPS | - | - | 0.23 | 0.29 | 0.32 | -0.21 | 0.02 | -0.89 | 0.06 | -0.46 | -0.58 | - | 0.70 | 2.38 | -0.47 | -0.09 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 0 | 483.00K | 1.46M | 1.20M | 1.19M | 1.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 41.56M | 46.78M | 44.51M | 46.08M | 48.54M | 56.57M | 55.52M | 52.09M | 59.96M | 61.41M | 57.63M | - | 69.54M | 75.13M | 72.44M | 71.92M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.86M | 58.79M | 55.31M | 56.15M |
| Cash & Equivalents | 245.38K | 230.58K | - | 0 | 0 | 66.37K | 887 | 268.20K | 473.00K | 480.00K | 351.00K | 352.00K | - | 1.03M | 960.00K | 916.00K | 1.66M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.44M | 21.66M | 21.64M | 20.70M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.97M | 19.28M | 14.88M | 17.00M |
| Total Liabilities | - | 22.27M | 26.28M | 23.38M | 24.14M | 25.71M | 34.29M | 33.20M | 32.26M | 38.87M | 41.43M | 38.92M | - | 41.46M | 39.78M | 38.43M | 37.37M |
| Current Liabilities | - | 20.40M | 25.01M | 20.13M | 19.37M | 13.37M | 19.67M | 20.31M | 18.05M | 24.89M | 22.23M | 19.54M | - | 26.40M | 26.58M | 21.43M | 29.84M |
| Long Term Debt | - | 1.73M | 812.92K | 2.87M | 4.25M | 4.07M | 5.95M | 4.89M | 4.35M | 3.62M | 3.18M | 5.87M | 8.96M | 6.85M | 5.82M | 8.63M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.51M | 14.18M | 18.04M | 15.71M |
| Total Equity | 18.73M | 19.29M | 20.51M | 21.14M | 21.94M | 22.83M | 22.27M | 22.32M | 19.82M | 21.09M | 19.98M | 18.72M | - | 28.08M | 35.34M | 34.01M | 34.55M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.69M | 2.69M | 2.76M | 2.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | 3.53M | 806.00K | 2.44M | 997.00K | 1.36M | - | 5.40M | 1.77M | -2.25M | 2.74M |
| Investing Cash Flow | - | - | - | - | - | - | -1.95M | -258.00K | -1.39M | -758.00K | 5.50M | - | -2.43M | -1.28M | -1.26M | -157.00K |
| Financing Cash Flow | - | - | - | - | - | - | -1.39M | -38.00K | -889.00K | -525.00K | -3.96M | - | -2.67M | -1.28M | 2.77M | -1.87M |
| Capital Expenditure | -626.63K | -1.27M | -4.43M | 1.20M | -2.19M | -1.68M | -1.96M | -813.00K | -1.40M | -719.00K | -485.00K | - | -2.44M | -1.28M | -1.27M | -661.00K |
| Free Cash Flow | - | - | - | - | - | - | 1.58M | -7.00K | 1.04M | 278.00K | 878.00K | - | 2.96M | 485.00K | -3.52M | 2.08M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | 309.00K | -796.00K | -748.00K | 719.00K |
| Share Buybacks | - | - | - | - | - | - | - | 30.00K | 276.00K | 130.00K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 11.5% | 11.7% | 11.6% | 11.8% | 11.9% | 10.5% | 11.9% | 10.8% | 11.7% | 10.8% | 9.3% | - | 15.3% | 16.6% | 13.1% | 15.2% |
| Operating Margin % | 1.2% | 1.3% | 1.4% | 1.3% | 1.2% | -0.4% | 0.5% | -1.1% | 1.1% | 0.2% | -0.6% | - | 2.9% | 4.3% | 0.3% | 1.0% |
| Net Margin % | 0.5% | 1.0% | 0.6% | 0.7% | 0.8% | -0.5% | 0.0% | -2.2% | 0.1% | -1.1% | -1.5% | - | 1.5% | 4.9% | -1.0% | -0.2% |
| ROE % | 2.6% | 5.8% | 3.0% | 3.6% | 3.9% | -2.6% | 0.2% | -12.3% | 0.8% | -6.1% | -8.3% | - | 7.2% | 19.4% | -3.8% | -0.7% |
| ROCE % | 5.8% | 6.9% | 6.0% | 5.4% | 3.8% | -1.1% | 1.8% | -3.7% | 3.6% | 0.6% | -1.6% | - | 9.0% | 12.3% | 0.7% | 2.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wells Fargo & Company | 2.67% | 76.09K | $897.11K |
| 2 | Renaissance Technologies, LLC | 2.19% | 62.60K | $738.04K |
| 3 | Vanguard Capital Management LLC | 0.92% | 26.25K | $309.45K |
| 4 | Chevy Chase Trust Holdings, LLC | 0.55% | 15.83K | $186.66K |
| 5 | Pathstone Holdings, LLC | 0.42% | 12.00K | $141.48K |
| 6 | Dimensional Fund Advisors LP | 0.37% | 10.62K | $125.26K |
| 7 | Morgan Stanley | 0.30% | 8.50K | $100.21K |
| 8 | Vanguard Fiduciary Trust Co | 0.18% | 5.21K | $61.44K |
| 9 | Blackrock Inc. | 0.16% | 4.46K | $52.54K |
| 10 | Larson Financial Group LLC | 0.01% | 241 | $2.84K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NSYS
Price-Driven Insight from (NSYS) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOcWxXN3M4bWdfcjhMNDgtellqRHVlbkJZMnNRYnQzS0lZSDRaZ1VoVjBqLTUyUktPVEdFcVNsNGV4Q1R1a2lwdWlQZjk2NDJISXFlUXJSMWthWE1LVVgxZS1tSXhWelFrSC1rZVJMUXV6U3N5LUk2X0FrWjZJREpHUFhVeU9Xa3Qzb2MzSj…
Nortech Systems Incorporated (NASDAQ: NSYS) Share Price, NSYS Stock News, NSYS Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE84Z09nX2c5QmNzV2N6YjhqSERId0VZWkhTOHRsMHhxZlloZmVSNktOTUdWdDc4SUlOSDRlSHVySFR2UnRzc1kyS0tUV0FHMnlwcG03SEhn?oc=5" target="_blank">Nortech Systems Incorporated (NASDAQ: NSYS) Share P…
NSYS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBKN01tOVRuQnBlYjkzSGdVa255ZlFWcGJXMG94R1pBUGpCRGl1VjRtdE9TLWZnYU1uNm5INGZYdFoyUjg2MFE?oc=5" target="_blank">NSYS</a> <font color="#6f6f6f">Finviz</font>…
Here's Why Nortech Systems (NASDAQ:NSYS) Can Afford Some Debt - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNOFc1X1N3ckp4SGZPdlg2RXl2TVFIQVIzZXUtdWRpWmtUNC1YRjA5SHJCRm5XaWtQZ3dTOFNmVVMzX2ZRaVFkblRPTGdjN1ZhXzBrN09yeFNFTElObjIwN0M0ekh0NF80WjJyUGM1MHZyc0V5MjdsbFJpSnhUcnJTSWpNcUNrMldsZ3ExVE…
Nortech Systems (NSYS) Q2 2026 Earnings Call Transcript - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcTZLRm44Zno5U2dWTGpwYVJMcE45UGp6M09QMWZvdHpud3d2dll2S0RDZW12Sm5ScmN4QXRPVnJEemJWUkFZZ2pYcXRqb0c2S3FLSFlfSjNQc3NKWllhR1NTM2VGVG1ub2RrUi1zZURqZFdPM2tZZXA2dmpXT3kzeUNsYlpmemxkbExyRG…
Nortech Systems (NSYS) Slips to $11.40 as Shares Test Mid-Range Territory - ETH Profile - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOaUlBa0tJVHBKbE4yZ1UxYnliVVdZLWFEZE9rV1hlN09DWDExOW02cUJPMHZnN1FfT1FvWW1lZ3BIQ1N5Q1E0QXV1RlFBbUVTajNBdUFSQndkMXBUUXJDT3lOODJEVkZJcUtCbEVYVzNsX2JGbmtpeEFQNDQ3eHh5c0ljNWRmTDMzYnluUE…
NSYS — Frequently Asked Questions
What is the current share price of Nortech Systems Incorporated (NSYS)?
As of 2026-09-19 21:16 PDT, Nortech Systems Incorporated (NSYS) trades at $11.72 on NasdaqCM. Its 52-week range is $6.80 to $17.66.
What is the market capitalisation of NSYS?
Nortech Systems Incorporated (NSYS) has a market capitalisation of $33.45M on NasdaqCM.
What is the P/E ratio of NSYS?
NSYS trades at a trailing price-to-earnings (P/E) ratio of 32.56. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.96.
What is the return on equity (ROE) of NSYS?
NSYS has a return on equity (ROE) of 3.00%. Its return on capital employed (ROCE) is 2.95%.
Is NSYS a good stock to buy?
This page provides a data-driven analysis of Nortech Systems Incorporated (NSYS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.